{"id":6638,"date":"2022-07-05T06:00:00","date_gmt":"2022-07-05T06:00:00","guid":{"rendered":"https:\/\/medical.ezag.com\/?post_type=news&p=6638"},"modified":"2022-07-05T06:04:20","modified_gmt":"2022-07-05T06:04:20","slug":"boston-updated-raml","status":"publish","type":"news","link":"https:\/\/medical.ezag.com\/en\/news\/boston-updated-raml\/","title":{"rendered":"Eckert and Ziegler receives updated handling license for US site"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t \t\n\t\t\t\t <\/div>\n\t\t\t\t
\n\t\t\t\t \t

Eckert and Ziegler receives updated handling license for US site<\/h1>\n\t\t\t\t <\/div>\n\t\t\t\t <\/div>\n\t\t\t\t <\/div>\n\t\t\t\t<\/section>
\n\t\t\t \t\t
\n\t\t \t\t

July 5, 2022 | Boston<\/p><\/div><\/div>\n\n\n\t\t

\n\t\t\t
\n\t\t\t\t\n\n\t\t\t\n\t\t\t
\n\t\t\t\t\n\n

Eckert & Ziegler has received an updated radioactive material license for their production facility in Boston, MA, USA. In addition to the production of Yttrium-90, the site will produce other medical isotopes and offer various services for the manufacturing and development of radiopharmaceuticals. This includes contract manufacturing and CMC services as well as GMP Suites, up to 15.000 sq. ft. of licensed radiation laboratories for pre-clinical development and production of clinical trial charges under (c)GMP conditions.<\/p>\n

\u201cThe revised RAML further increases our production capacity and capabilities to offer CMO services to both US and international customers from our Boston facility\u201d stated Jay R. Simon, Managing Director of Eckert & Ziegler Radiopharma, Inc and responsible for the Boston site. \u201cApart from further upscaling of our Yttrium-90 production, it also enables our team to work with the medical radioisotopes in the greatest demand including Ac-225 and Lu-177. By this we are able to support innovative companies in their activities to access the markets.\u201d<\/p>\n

\u201cBesides the provision of local infrastructure, it is our goal to offer services to customers and partners on an international level\u201d added Dr. Lutz Helmke, Executive Director and COO of the Medical segment. \u201cThe updated license perfectly supports this as we continue to move closer to the specifications of our established German site in Braunschweig. This further facilitates our partners to transfer their clinical programs internationally and to mirror manufacturing processes at the different Eckert & Ziegler sites.\u201d<\/p>\n

To meet the increasing demand for radiopharmaceutical substances, Eckert & Ziegler extensively invests in its production sites. Two new facilities are under construction in Jintan, China and Berlin, Germany. The existing sites in Braunschweig, Germany and Boston, USA are updated with additional manufacturing equipment. This will enable the company to be a comprehensive radiopharmaceutical contract manufacturer for phase I, II and III clinical scale products and commercial use.<\/p>\n

About Eckert & Ziegler. <\/strong><\/p>\n

Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche B\u00f6rse. Contributing to saving lives.<\/strong><\/p>\n

Contact<\/strong><\/p>\n

Eckert & Ziegler Medical
Jan Sch\u00f6pflin, Marketing
Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 \/ 94 10 84-252, jan.schoepflin@ezag.de; www.medical.ezag.com<\/p>\n\n\n\t\t\t<\/div>\n\t\n\n\t\t\t<\/div>\n\t\t<\/section>\n\t\n\n\n\t\t